Display options
Cite
Eom YH, Kim HS, Lee A, et al. BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer. J Breast Cancer. 2016;19(3):252-260doi: 10.4048/jbc.2016.19.3.252.
Eom, Y. H., Kim, H. S., Lee, A., Song, B. J., & Chae, B. J. (2016). BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer. Journal of breast cancer, 19(3), 252-260. https://doi.org/10.4048/jbc.2016.19.3.252
Eom, Yong Hwa, et al. "BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer." Journal of breast cancer vol. 19,3 (2016): 252-260. doi: https://doi.org/10.4048/jbc.2016.19.3.252
Eom YH, Kim HS, Lee A, Song BJ, Chae BJ. BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer. J Breast Cancer. 2016 Sep;19(3):252-260. doi: 10.4048/jbc.2016.19.3.252. Epub 2016 Sep 23. PMID: 27721874; PMCID: PMC5053309.
Copy Download .nbib Format: NLM
Share it on

J Breast Cancer. 2016 Sep;19(3):252-260. doi: 10.4048/jbc.2016.19.3.252. Epub 2016 Sep 23.

BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer.

Journal of breast cancer

Yong Hwa Eom, Hyung Suk Kim, Ahwon Lee, Byung Joo Song, Byung Joo Chae

Affiliations

  1. Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  2. Department of Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  3. Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.; Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.

PMID: 27721874 PMCID: PMC5053309 DOI: 10.4048/jbc.2016.19.3.252

Abstract

PURPOSE: B-cell lymphoma 2 (BCL2) is an antiapoptosis protein and an important clinical breast cancer prognostic marker. As the role of BCL2 is dependent on the estrogen receptor (ER) status, this effect might differ according to molecular subtypes. The aim of this study was to evaluate the relationship between the prognostic outcomes and BCL2 expression among the molecular subtypes.

METHODS: We retrieved the data of 1,356 patients who were newly diagnosed with malignant breast cancer between November 2006 and November 2011. Immunohistochemistry was used to measure ER, progesterone receptor, human epidermal growth factor receptor 2 (HER2), Ki-67, and BCL2 expression. We classified breast cancer into five molecular subtypes based on the 13th St. Gallen International Expert Consensus, including luminal A, luminal B (HER2-negative), luminal B (HER2-positive), HER2-overexpression, and triple-negative subtypes. We analyzed the clinicopathological features and assessed the correlation between BCL2 expression and clinical outcomes, such as relapse-free survival (RFS) and disease-specific survival (DSS) according to the five molecular subtypes.

RESULTS: A total of 605 cases of breast cancer (53.8%) showed BCL2 expression. BCL2-positive expression was associated with young age (<50 years,

CONCLUSION: The prognostic role of BCL2 expression in breast cancer is subtype-specific. BCL2 expression differs according to the molecular subtype and is a good prognostic marker for only luminal A breast cancer.

Keywords: B-cell lymphoma 2 protein; Breast neoplasms; Prognosis; Tumor biomarkers

Conflict of interest statement

The authors declare that they have no competing interests.

References

  1. Pathol Oncol Res. 2002;8(1):26-30 - PubMed
  2. Breast Cancer Res Treat. 2015 Feb;150(1):141-8 - PubMed
  3. Int J Cancer. 2012 Oct 1;131(7):E1109-19 - PubMed
  4. Med Oncol. 2011 Dec;28 Suppl 1:S55-61 - PubMed
  5. Breast Cancer Res Treat. 2012 Feb;132(1):51-9 - PubMed
  6. Tumour Biol. 2014 Dec;35(12):12255-63 - PubMed
  7. Breast Cancer Res Treat. 2015 Jun;151(2):325-33 - PubMed
  8. Clin Cancer Res. 2006 Apr 15;12(8):2468-75 - PubMed
  9. Br J Cancer. 2010 Aug 24;103(5):668-75 - PubMed
  10. Ann Oncol. 2013 Nov;24(11):2801-7 - PubMed
  11. Ann Oncol. 2013 Sep;24(9):2206-23 - PubMed
  12. Semin Oncol. 2003 Oct;30(5 Suppl 16):133-42 - PubMed
  13. Tumour Biol. 2015 Jun;36(6):4243-52 - PubMed
  14. J Surg Res. 1998 Apr;76(1):22-6 - PubMed
  15. Br J Cancer. 1995 Aug;72(2):354-60 - PubMed
  16. Int J Cancer. 1995 May 4;61(3):301-5 - PubMed
  17. Mol Hum Reprod. 1998 Dec;4(12):1099-109 - PubMed
  18. BMC Cancer. 2006 Jul 13;6:187 - PubMed
  19. Cancer Res. 1995 Sep 1;55(17 ):3902-7 - PubMed
  20. Clin Cancer Res. 1995 Feb;1(2):189-98 - PubMed
  21. Curr Drug Targets. 2014;15(12):1166-75 - PubMed
  22. Target Oncol. 2014 Dec;9(4):367-79 - PubMed
  23. Br J Cancer. 1999 Oct;81(3):387-92 - PubMed
  24. Cancer Cell. 2013 Jul 8;24(1):7-9 - PubMed
  25. Breast Cancer Res Treat. 2015 Feb;149(3):631-43 - PubMed
  26. Cancer Biomark. 2010;6(2):63-72 - PubMed
  27. Breast Cancer Res Treat. 2009 May;115(2):343-8 - PubMed
  28. J Cell Sci. 2009 Feb 15;122(Pt 4):437-41 - PubMed
  29. Hum Pathol. 2012 Jan;43(1):23-30 - PubMed

Publication Types